



COLORADO

Department of Health Care
Policy & Financing

Drug Utilization Review Board Health First Colorado, Colorado's Medicaid program

DUR Board Members	DUR Team
Brian Jackson, MD, MA (Chair)	Jeffrey Taylor, PharmD (HCPF)
Liza Claus, PharmD (Vice Chair)	Veronia Garcia, PharmD (HCPF)
Todd Brubaker, DO	Rachele Poissant, PharmD (HCPF)
Shilpa Klocke, PharmD	Julia Rawlings, PharmD (CO-DUR)
Kenneth MacIntyre, DO	Robert L Page II, PharmD, MSPH (CO-DUR)
Ingrid Pan, PharmD	Gina Moore, PharmD, MBA (CO-DUR)
Marshal Ash, DO	Heather Anderson, PhD (CO-DUR)
	Garth Wright, MPH (CO-DUR)

MEETING AGENDA

November 12, 2024

Open Session 1:00 pm to 5:00 pm

Zoom Link will be posted prior to the meeting at

<https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board>

1. Call to Order
2. Roll Call and Introductions
3. Virtual Meeting Information and General Announcements
4. Colorado Department of Health Care Policy and Financing Updates
5. Final Approval of Minutes from the August 13, 2024 Meeting
6. Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest

Presentations:

- Agenda items must be approved in advance, including requests to present information. Please contact DUR Pharmacist Jeffrey Taylor at jeffrey.taylor@state.co.us
- Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours prior to the start of the meeting

7. Clinical Updates and General Orders

- FDA Safety Communications
- FDA New Product Update
- Quarterly Module Summaries
- Retrospective DUR Reports
- Quarterly Drug Utilization Reports

8. New Business (open for public testimony and DUR Board review)

A. Proposed Coverage Criteria for Preferred Drug List (PDL) Drug Classes

(Current PDL available for reference at <https://hcpf.colorado.gov/pharmacy-resources#PDL>)

- Human Immunodeficiency Virus (HIV) Treatments
- Immune Globulins
- Methotrexate Products
- Targeted Immune Modulators
- Respiratory Agents
 - Inhaled Beta2 Agonists
 - Short-acting
 - Long-acting
 - Phosphodiesterase Inhibitors (PDEIs)

Mass Review Drug Classes*

- Antibiotics, inhaled
- Antiherpetic Agents - oral and topical
- Fluoroquinolones, oral
- Hepatitis C Virus Treatments
 - Direct Acting Antivirals
 - Ribavirin
- Antihistamines
 - Newer Generation
 - Antihistamine/Decongestant Combinations
- Intranasal Rhinitis Agents
- Leukotriene Modifiers
- Epinephrine Products
- Newer Hereditary Angioedema (HAE) Products
- Respiratory Agents
 - Inhaled Anticholinergics
 - Inhaled Anticholinergic Combinations
 - Inhaled Corticosteroids
 - Inhaled Corticosteroid Combinations

**Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria currently implemented for these designated classes. The DUR Board may determine if designated mass review drug classes will undergo full review, based on board vote.*

B. Proposed Coverage Criteria for Non-PDL Products

(Current coverage criteria for non-PDL products can be referenced on Appendix P at <https://hcpf.colorado.gov/pharmacyresources#PDLP> for the pharmacy benefit and on Appendix Y at <https://hcpf.colorado.gov/physician-administered-drugs> for the medical benefit. Products listed below that are undergoing initial review of newly proposed criteria will not be listed on the posted documents until such time that proposed criteria undergoes review and finalization)

- Kisunla (donanemab-azbt) - proposed criteria for the pharmacy and medical benefit
- Miplyffa (arimoclomol)
- Aqneursa (levacetylleucine)
- Duvyzat (givinostat)
- OTC Multivitamin + Iron (Poly-Vi-Sol + Iron) Drops

- Iqirvo (elafibrano)
- Livdelzi (seladelpar)
- Xolremdi (mavorixafor)
- Vafseo (vadadustat)

9. Adjournment

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the 504/ADA Coordinator or send an email to hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

Improving health care equity, access, and outcomes for the people we serve while
saving Coloradans money on health care and driving value for Colorado.
www.colorado.gov/hcpf

